MetaCap

Galectin Therapeutics (GALT) vs Prelude Therapeutics (PRLD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prelude Therapeutics (PRLD) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 93.4% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -76.9% for PRLD. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $258.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GALT-49.72%PRLD+93.41%
+315%+118%-79%
Nov 21, 20251 yearNov 20, 2026
GALT0.00%PRLD-77.66%
+144%+19%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GALT versus PRLD key metrics
MetricGALTPRLD
Share price$2.69$3.23
Market cap$271.35M$258.63M
1-day change-4.27%-0.77%
YTD return-35.34%+11.38%
1-year return-49.72%+93.41%
5-year return+4.67%-76.93%
EPS (TTM)$-0.32$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$12.14M
Revenue growth (YoY)—+73.43%
Net income (latest FY)$-30.84M$-99.50M
Operating margin—-861.33%
Net margin—-819.59%
52-week high$7.13$6.83
52-week low$2.03$1.30
Distance from 52-week high-62.27%-52.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.92%+172.45%
Average volume252.31K432.74K
Shares outstanding100.88M65.34M
Employees979
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRLD has outperformed GALT by 143.1 percentage points over the past year.

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Prelude Therapeutics

PRLD stock →

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

GALT vs PRLD FAQ

Which is bigger, Galectin Therapeutics or Prelude Therapeutics?

Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $258.63M for Prelude Therapeutics (PRLD).

Which stock has performed better over the past year, GALT or PRLD?

PRLD returned +93.41% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Galectin Therapeutics and Prelude Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons